FY2024 EPS Estimates for Avantor Decreased by Zacks Research

Avantor, Inc. (NYSE:AVTR) – Stock analysts at Zacks Research reduced their FY2024 EPS estimates for shares of Avantor in a research note issued on Friday, November 15th. Zacks Research analyst D. Dey now expects that the company will earn $0.98 per share for the year, down from their previous forecast of $1.01. The consensus estimate for Avantor’s current full-year earnings is $0.98 per share. Zacks Research also issued estimates for Avantor’s Q4 2024 earnings at $0.25 EPS, Q1 2025 earnings at $0.25 EPS, Q2 2025 earnings at $0.27 EPS, Q4 2025 earnings at $0.31 EPS, FY2025 earnings at $1.10 EPS, Q2 2026 earnings at $0.28 EPS and FY2026 earnings at $1.27 EPS.

AVTR has been the subject of a number of other research reports. Barclays lowered their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Morgan Stanley boosted their target price on Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a research report on Monday, July 29th. TD Cowen lifted their price objective on Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Stifel Nicolaus upped their target price on shares of Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Monday, July 29th. Finally, Robert W. Baird reduced their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Avantor currently has an average rating of “Moderate Buy” and a consensus target price of $27.57.

Avantor Trading Down 2.7 %

Shares of NYSE AVTR opened at $20.18 on Monday. Avantor has a 1-year low of $19.23 and a 1-year high of $28.00. The company has a 50-day moving average of $24.41 and a two-hundred day moving average of $23.97. The company has a market cap of $13.73 billion, a PE ratio of 43.87, a P/E/G ratio of 2.51 and a beta of 1.35. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84.

Insiders Place Their Bets

In related news, CAO Steven W. Eck sold 3,525 shares of the stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. This represents a 10.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Empowered Funds LLC acquired a new stake in Avantor in the 1st quarter valued at approximately $250,000. SG Americas Securities LLC bought a new position in shares of Avantor during the 1st quarter worth approximately $159,000. Intech Investment Management LLC raised its holdings in shares of Avantor by 60.2% in the first quarter. Intech Investment Management LLC now owns 28,554 shares of the company’s stock valued at $730,000 after purchasing an additional 10,727 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Avantor by 45.8% in the first quarter. Acadian Asset Management LLC now owns 22,678 shares of the company’s stock worth $579,000 after purchasing an additional 7,120 shares in the last quarter. Finally, Edgestream Partners L.P. bought a new stake in shares of Avantor in the first quarter worth $1,242,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.